-
1
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Published 2017“…American Society of Hematology…”
Journal article -
2
Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the ra...
Published 2021“…American Society of Hematology…”
Conference item -
3
Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (A...
Published 2021“…American Society of Hematology…”
Conference item -
4
International Consensus Classification of myeloid neoplasms and acute leukemia: Integrating morphological, clinical, and genomic data.
Published 2022“…American Society of Hematology…”
Journal article -
5
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Published 2022“…American Society of Hematology…”
Journal article